Nexalin Technology Advances FDA Strategy for Alzheimer's Treatment

Key Facts

1Nexalin Technology completed high-level meetings in the U.S. and China to advance its global clinical strategy for Alzheimer's treatment.

2The company held a productive Q-Submission interaction with the U.S. Food and Drug Administration (FDA).

3These meetings represent key milestones in the preparation of the De Novo application with the FDA.

Nexalin Technology (Nasdaq: NXL) has announced significant progress in its regulatory path for its non-invasive Deep Intracranial Frequency Stimulation (DIFS) technology, specifically targeting Alzheimer's disease and dementia. The company successfully completed high-level meetings in both the U.S. and China to solidify its global clinical strategy. A key highlight was the productive Q-Submission interaction with the U.S. Food and Drug Administration (FDA), which serves as a crucial step toward a formal De Novo application. These discussions aim to align clinical data and regulatory requirements across international markets. This advancement underscores Nexalin's commitment to delivering innovative treatments for neurodegenerative conditions. Investors are closely monitoring these milestones as the company moves closer to potential market authorization.